Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476421 | 0.92 | NPC1 (0.53) | PPARGPPARANPC1RAB9APOLB | |
| SCHEMBL7068337 | 0.87 | CYP3A4 (0.59) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9950393 | 0.85 | PPARG (0.60) | PPARGPPARANPC1RAB9APOLB | |
| SCHEMBL27891386 | 0.85 | NPC1 (0.53) | PPARGPPARANPC1RAB9APOLB | |
| SCHEMBL26125762 | 0.84 | ALDH1A1 (0.50) | PPARGPPARANPC1RAB9APOLB | |
| SCHEMBL23412255 | 0.83 | KDM4E (0.62) | PPARGPPARANPC1RAB9APOLB | |
| SCHEMBL23412356 | 0.83 | KDM4E (0.62) | PPARGPPARANPC1RAB9APOLB | |
| SCHEMBL23412131 | 0.83 | KDM4E (0.62) | PPARGPPARANPC1RAB9APOLB | |
| SCHEMBL28900536 | 0.83 | MCL1 (0.47) | PPARGPPARANPC1RAB9APOLB | |
| SCHEMBL29133435 | 0.83 | PDE10A (0.58) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103044391-B | A kind of DPP-IV inhibitor efficiently | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-103044392-B | A kind of preparation method of efficient DPP-IV inhibitor | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO.,LTD. (CN) | 2015-10-14 | — | — | CN | disclosed |
| CN-103044391-A | High-efficient DPP (dipeptidyl peptidase)-IV inhibitor | GUANGZHOU INST BIOMED & HEALTH | 2013-04-17 | — | — | CN | disclosed |
| CN-103044392-A | Preparation method of high-efficient DPP (dipeptidyl peptidase)-IV inhibitor | LIANYUNGANG RUIZHONG PHARMACEUTICAL CO LTD | 2013-04-17 | — | — | CN | disclosed |
| US-7247617-B2 | Sixteen-member macrolide antiinfective agents | KOSAN BIOSCIENCES INCORPORATED (US) | 2007-07-24 | — | — | US | disclosed |
| WO-2006017250-A2 | SIXTEEN-MEMBERED MACROLIDE ANTIINFECTIVE AGENTS | KOSAN BIOSCIENCES INCORPORATED (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060014707-A1 | Sixteen-member macrolide antiinfective agents | KOSAN BIOSCIENCES INCORPORATED INTELLECTUAL PROPERTY DEPT. | 2006-01-19 | — | — | US | disclosed |
| CN-1564820-A | Heterocyclic compounds for use in the treatment of disorders of the urinary tract | RECORDATI CHEM PHARM (CH) | 2005-01-12 | — | — | CN | disclosed |
| CN-1476445-A | 4- (biphenylcarbonylamino) piperidine derivatives as MTP inhibitors | Ĭ��ר������˾ | 2004-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014707-A1 | Sixteen-member macrolide antiinfective agents | MRPL21, MRPS18B, MRPS18A | PPARG 2876/4885PPARA 3163/4885NPC1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.